DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Up 72.5% in August

Key Points

• Short interest in DBV Technologies S.A. (NASDAQ:DBVT) increased by 72.5% in August, reaching a total of 18,800 shares by August 31st.
• Several hedge funds and institutional investors have newly acquired stakes in DBV Technologies, with a combined investment of around $9.6 million from multiple firms in the 2nd quarter.
• The company's latest earnings report showed a loss of ($1.55) per share, significantly missing analyst expectations, although it achieved revenues of $1.74 million for the quarter.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 18,800 shares, a growth of 72.5% from the August 15th total of 10,900 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average trading volume of 29,800 shares, the days-to-cover ratio is presently 0.6 days. Based on an average trading volume of 29,800 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.1% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. The Goldman Sachs Group upgraded DBV Technologies to a "sell" rating and set a $7.25 price target for the company in a research note on Thursday, May 29th. Citigroup restated an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. Wall Street Zen downgraded DBV Technologies from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. JMP Securities restated a "market outperform" rating and issued a $21.00 target price on shares of DBV Technologies in a research note on Thursday, June 26th. Finally, Lifesci Capital upgraded DBV Technologies to a "strong-buy" rating in a research note on Thursday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $14.75.

Institutional Trading of DBV Technologies

Several institutional investors and hedge funds have recently modified their holdings of the business. Vivo Capital LLC purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at about $9,659,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at about $9,659,000. MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at about $9,649,000. Octagon Capital Advisors LP purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at about $9,315,000. Finally, Nan Fung Trinity HK Ltd. purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at about $340,000. Hedge funds and other institutional investors own 71.74% of the company's stock.

DBV Technologies Price Performance

Shares of NASDAQ:DBVT traded down $0.09 on Friday, hitting $9.50. The company's stock had a trading volume of 7,870 shares, compared to its average volume of 31,166. The company has a 50-day simple moving average of $9.62 and a 200 day simple moving average of $8.68. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $12.78. The company has a market capitalization of $260.30 million, a PE ratio of -1.99 and a beta of -0.36.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($1.55) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.34). DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. The business had revenue of $1.74 million during the quarter, compared to analysts' expectations of $0.64 million. On average, equities research analysts expect that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.